Intellia Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Intellia Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 30% in 3 years; of every extra $100 of sales, $395 became extra profit. Higher than 92% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-54.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 73% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Less steady than 51% of Healthcare companies in United States.
Growth Efficiency Ratio
$395Sales grew 30% in 3 years; of every extra $100 of sales, $395 became extra profit.
Higher than 92% of Healthcare companies in United States.
Asset Productivity Ratio
+30% / -45%In 3 years sales changed by +30% while total assets changed by -45%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-14.9×Operating cash was negative last year, while some debt falls due within a year.
Higher than 50% of Healthcare companies in United States.
Cash Cushion Ratio
+23%Cash, after subtracting all debt, equals 23% of its market value (net cash).
Higher than 65% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Intellia Therapeutics, Inc. made a loss over the last year. Intellia Therapeutics, Inc. owes $0.15 for every $1 it owns. Intellia Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossIntellia Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.16The share price is 2.16 times Intellia Therapeutics, Inc.'s book value per share, lower than 55% of Healthcare companies in United States.
Market cap
$1.6 BThe total market value of all of Intellia Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 70% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$728 MWhat Intellia Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$5.19Net worth divided by the number of shares. The share price of $11.21 is 2.2 times this, which is the P/B above.
Return on equity (ROE)
-55.4%Intellia Therapeutics, Inc. lost 55.4% of its shareholders' money over the last year, lower than 54% of Healthcare companies in United States.
Owes vs Owns
0.15×Intellia Therapeutics, Inc. owes $0.15 for every $1 it owns (low), lower than 80% of Healthcare companies in United States.
Dividend yield
NoneIntellia Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+17%Revenue rose 17% in the year to Dec 2025, and grew 9% a year on average over 3 years.
Profit growth
LossIntellia Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-609.9%Intellia Therapeutics, Inc. lost $610 for every $100 of revenue.
Cash vs debt
Net cashIntellia Therapeutics, Inc. held $357 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Intellia Therapeutics, Inc.: $1.6 B ÷ $728 M (30 Jun 2026) = 2.2.
What is Intellia Therapeutics, Inc.'s return on equity?
Intellia Therapeutics, Inc. lost 55.4% of its shareholders' money over the last year, lower than 54% of Healthcare companies in United States.
How much does Intellia Therapeutics, Inc. owe compared with what it owns?
Intellia Therapeutics, Inc. owes $0.15 for every $1 it owns (low), lower than 80% of Healthcare companies in United States.
Does Intellia Therapeutics, Inc. pay a dividend?
No. Intellia Therapeutics, Inc. does not currently pay a dividend.
Is Intellia Therapeutics, Inc.'s revenue growing?
Revenue rose 17% in the year to Dec 2025, and grew 9% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.